Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada

References

• Haider S, Rotstein C, Horn D, et al. The prospective antifungal therapy alliance® registry: a two-centre Canadian experience. Can J Infect Dis Med Microbiol. 2014;25(1):17–23.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Fungal diseases 2017 [cited 2018 Jun 1]. Available from: https://www.cdc.gov/fungal/infections/index.html
   Google Scholar
• Lanternier F, Sun H, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54(11):1–8.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D, Lewis R. How I treat mucormycosis. Blood. 2011;118(5):1216–1224.
   PubMed Web of Science ®Google Scholar
• Denning D. Aspergillosis. In: Kasper D, Fauci A, Hauser S et al., editors Harrison’s principles of internal medicine. 19e ed. New York (NY): McGraw-Hill Education; 2015.
   Google Scholar
• Spellberg B, Ibrahim A. Mucormycosis. In: Kasper D, Fauci A, Hauser S, et al. editors. Harrison’s principles of internal medicine. 19e ed. New York (NY): McGraw-Hill Education; 2015.
   Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
   PubMed Web of Science ®Google Scholar
• Maturu V, Agarwal R. Reversed halo sign: a systematic review. Respir Care. 2014;59(9):1440–1449.
   PubMed Web of Science ®Google Scholar
• Patterson T, Thompson G, Denning D, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis R, Kontoyiannis D. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–509.
   PubMed Web of Science ®Google Scholar
• Ullmann A, Aguado J, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–e38.
   PubMed Web of Science ®Google Scholar
• AVIR Pharma Inc. Cresemba - Product monograph; 2017 Oct 11.
   Google Scholar
• Tissot F, Samir A, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444.
   PubMed Web of Science ®Google Scholar
• Jenks J, Salzer H, Prattes J, et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033–1044.
   PubMed Web of Science ®Google Scholar
• Marty F, Ostrosky-Zeichner L, Cornely O, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Marr K, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
   PubMed Web of Science ®Google Scholar
• Floros L, Pagliuca A, Al Taie A, et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. J Med Econ. 2020;23(1):86–97.
   PubMed Web of Science ®Google Scholar
• Ellison LF. Progress in net cancer survival in Canada over 20 years. Health Ref. 2018. 29(9):10-18.
   Google Scholar
• Beusterien K, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8(50):50.
   PubMedGoogle Scholar
• Leunis A, Redekop W, Uyl-de Groot C, et al. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93(3):198–206.
   PubMed Web of Science ®Google Scholar
• Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). Clin Microbiol Infect. 2012;18(10):E396–400.
   PubMed Web of Science ®Google Scholar
• Seidel D, Durán Graeff L, Vehreschild M, et al. FungiScope™ - Global emerging fungal infection registry. Mycoses. 2017;60(8):508–516.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Consumer price index, annual average, not seasonally adjusted (Table: 18-10-0005-01). 2020 [cited 2018 Jun 1]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada, 4th edition 2017 [cited 2018 Jun 1]. Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition
   Google Scholar
• Ontario. Ontario Drug Benefit Formulary. 2019 [cited 2018 Jun 1]. Available from: https://www.formulary.health.gov.on.ca/formulary/
   Google Scholar
• Association québécoise des pharmaciens propriétaires (AQPP). Liste de l’AQPP: January 2020; 2020.
   Google Scholar
• Canadian Institute for Health Information. Patient cost estimator 2019 [cited 2018 Jun 1]. Available from: https://www.cihi.ca/en/patient-cost-estimator
   Google Scholar
• Ontario. Ontario Care Costing (OCC)- Cost analysis tool 2020 [cited 2018 Jun 1]. Available from: https://hsimi.ca/occp/occpreports/
   Google Scholar
• Statistics Canada. Average usual hours and wages by selected characteristics, monthly, unadjusted for seasonality, last 5 months (Table: 14-10-0320-01). 2020 [cited 2018 Jun 1]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1410032001
   Google Scholar
• Pfizer Canada Inc. Vfend - Product monograph; 2014 Oct 30.
   Google Scholar
• Astellas Pharma Canada Inc. AmBisome - Product monograph; 2011 Jul 29.
   Google Scholar
• Merck Canada Inc. Posanol - Product monograph; 2017 Jul 14.
   Google Scholar
• Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for the tretament of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532–539.
   PubMed Web of Science ®Google Scholar
• Ament A, Hubben M, Verweij P, et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother. 2007;60(2):385–393.
   PubMed Web of Science ®Google Scholar
• Stam W, O’Sullivan A, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008;81(6):467–474.
   PubMed Web of Science ®Google Scholar
• Walsh T, Teppler H, Donowitz G, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391–1402.
   PubMed Web of Science ®Google Scholar
• Dufresne S, Cole D, Denning D, et al. Serious fungal infections in Canada. Eur J Clin Microbiol Infect Dis. 2017;36(6):987–992.
   PubMed Web of Science ®Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: iSPORGood research practices task force report. Value Health. 2009;12(4):409–418.
   PubMed Web of Science ®Google Scholar
• Goeree R, Burke N, O’Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin. 2007;23(4):671–682.
   PubMed Web of Science ®Google Scholar
• Azanza J, Grau S, Vázquez L, et al. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. J Med Econ. 2020;23(1):86–97.
   PubMed Web of Science ®Google Scholar
• Luong M, Al-Dabbagh M, Groll A, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–1799.
   PubMed Web of Science ®Google Scholar